<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Benztropine - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Benztropine</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Neuro / Psych</div>
      <h1>Benztropine</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Benztropine 1mg Tablets</li>
          <li>Benztropine 1mg/mL Injection</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Acute dystonic reaction (drug-induced extrapyramidal symptoms)</strong>
            <ul>
              <li><strong>IM/IV:</strong> 1–2 mg as a single dose; may repeat after 30 minutes if needed</li>
              <li>Onset: IM within 15 minutes; IV within minutes</li>
              <li>Most acute reactions respond to initial 1–2 mg dose</li>
            </ul>
          </li>
          <li><strong>Prevention/maintenance (if continuing causative agent)</strong>
            <ul>
              <li><strong>PO:</strong> 1–2 mg once or twice daily</li>
              <li>Adjust dose based on response and tolerability (range 0.5–6 mg daily in divided doses)</li>
              <li>Use lowest effective dose</li>
            </ul>
          </li>
          <li><strong>Parkinsonism (adjunct therapy)</strong>
            <ul>
              <li><strong>PO:</strong> Initial 0.5–1 mg at bedtime; increase gradually as needed (range 1–6 mg daily)</li>
              <li>Specialized use; follow neurology/medical direction if applicable</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Treatment of acute dystonic reactions (muscle spasm, torticollis, oculogyric crisis) from antipsychotics or other dopamine antagonists</li>
          <li>Prevention of drug-induced extrapyramidal symptoms when continuing causative medication</li>
          <li>Adjunct treatment of Parkinson's disease and drug-induced parkinsonism</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to benztropine or anticholinergic agents</li>
          <li>Narrow-angle glaucoma</li>
          <li>Tardive dyskinesia (anticholinergics do not help and may worsen)</li>
          <li>Myasthenia gravis, obstructive GI/GU disease</li>
          <li>Caution in older adults: increased risk of confusion, cognitive impairment, urinary retention, falls</li>
          <li>Caution in hot environments: decreased sweating can lead to hyperthermia</li>
          <li>Prostatic hypertrophy/urinary retention risk</li>
          <li>Significant cardiovascular disease (tachycardia risk)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Anticholinergic effects: dry mouth, blurred vision, urinary retention, constipation</li>
          <li>CNS: sedation, confusion, dizziness, memory impairment (especially older adults)</li>
          <li>Decreased sweating, heat intolerance</li>
          <li>Tachycardia</li>
          <li>Nausea, vomiting</li>
          <li>Paradoxical worsening of movement disorders with excessive dosing</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li><strong>IM injection:</strong> 1 mg/mL solution; inject deep IM into large muscle (deltoid or gluteal)</li>
          <li><strong>IV injection:</strong> may give undiluted 1 mg/mL solution by slow IV push if needed for urgent dystonic reaction</li>
          <li><strong>PO tablets:</strong> may take with or without food; take at consistent times</li>
          <li>For acute dystonic reaction: IM route preferred if IV access not established; response usually rapid</li>
          <li>After acute treatment: observe for recurrence; consider short oral course if continuing causative medication</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Clinical response to acute dystonic symptoms (should improve within 15–30 minutes after IM/IV dose)</li>
          <li>Recurrence of symptoms (may require repeat dosing or oral continuation)</li>
          <li>Anticholinergic side effects (dry mouth, urinary retention, confusion)</li>
          <li>Mental status changes, especially in older adults</li>
          <li>If used chronically: reassess ongoing need and consider gradual taper when appropriate</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Acute dystonic reactions can be distressing and alarming; reassure patient that symptoms typically resolve rapidly with treatment</li>
          <li>If dystonia from antipsychotic/antiemetic (metoclopramide, prochlorperazine): consider discontinuing or switching causative agent</li>
          <li>Heat stress: anticholinergic effects impair thermoregulation; monitor in hot/humid conditions and ensure adequate hydration</li>
          <li>Cognitive/sedation effects: caution with watchkeeping and safety-sensitive duties</li>
          <li>Document triggering medication, symptom onset, and response to treatment for future reference</li>
          <li>If recurrent dystonia: consider prophylactic oral benztropine while continuing causative drug, or seek alternative to causative agent</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (benztropine mesylate injection): <a href="https://pdf.hres.ca/dpd_pm/00051869.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00051869.PDF</a></li>
          <li>Health Canada product monograph (benztropine tablets - PMS-Benztropine): <a href="https://pdf.hres.ca/dpd_pm/00051627.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00051627.PDF</a></li>
          <li>Medscape - Benztropine: <a href="https://reference.medscape.com/drug/cogentin-benztropine-343411" target="_blank" rel="noopener">https://reference.medscape.com/drug/cogentin-benztropine-343411</a></li>
          <li>UpToDate - Drug-induced acute dystonia (institutional access may be required)</li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
